Magnolia Neurosciences Corporation

Aducanumab, Biogen, Inc.'s on-again off-again experimental candidate for Alzheimer’s disease, took a drubbing during a Food and Drug Administration (FDA) advisory committee on 6 November 2020, a sta

Biopharmaceutical companies have announced an abundance of investment in their companies from US government sources recently, which adds to the flurry of new investment funds backing drug developers,

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmace

Vaccinex Inc. and Aridis Pharmaceuticals Inc. were the first and second drug developers to launch initial public offerings in the US during the first half of August. And since the warm month is lag